The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Jangra, Sonia, Ye, Chengjin, Rathnasinghe, Raveen, Stadlbauer, Daniel, Krammer, Florian, Simon, Viviana, Martinez-Sobrido, Luis, García-Sastre, Adolfo, Schotsaert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852247/
https://www.ncbi.nlm.nih.gov/pubmed/33532796
http://dx.doi.org/10.1101/2021.01.26.21250543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852247/
https://www.ncbi.nlm.nih.gov/pubmed/33532796
http://dx.doi.org/10.1101/2021.01.26.21250543

Ejemplares similares